Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

129 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-07

Study Completion Date

2023-04-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a multicenter, open-label, active-controlled study to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 maintenance doses in de novo liver transplant recipients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

NCT02217410

Kidney Transplantation

COMPLETED PHASE1/PHASE2

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

NCT01150097

Liver Transplant Recipient

COMPLETED PHASE3

Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen

NCT00286871

Chronic Hepatitis C Organ Transplantation Immunosuppression

COMPLETED PHASE1

Steroid Free Immunosuppression in Liver Transplantation

NCT00296244

Liver Cirrhosis Liver Transplant Disorder

COMPLETED PHASE4

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

NCT00622869

Liver Transplantation

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study was designed as a randomized, 36-month clinical trial comprised of:

* A screening period (up to 2 months) starting from informed consent, screening visit, and including successful liver transplantation (LTx).
* A run-in treatment period following successful transplantation that ended on the day of randomization or randomization failure, at Day 8 (with visit window of +/- 2 days) post-LTx.
* The primary treatment period (Treatment Period 1) starting at randomization Day 8 +/- 2 post-LTx up to Month 12 followed by a 12-month follow-up treatment period (Treatment Period 2) until Month 24.
* The long-term extension period (Treatment Period 3) starting post Month 24 until the end of the study (EOS).
* A minimum 12-week safety follow-up period for all patients after EOS.

The study was terminated following less favorable efficacy by Iscalimab (CFZ533) in liver transplant patients compared to tacrolimus.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplant Rejection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAC Control

Tacrolimus (TAC) + Mycophenolate mofetil (MMF) + Corticosteroids (CS) up to End of Study (EOS). Initial TAC target trough were between 5-15 ng/mL during the run-in period. From randomization onwards, the TAC levels were adjusted as per local label.

Group Type ACTIVE_COMPARATOR

Tacrolimus - MMF - corticosteroids

Intervention Type DRUG

Standard of care immunosuppresive regimen

CFZ533 600 mg regimen

Loading doses of 30 mg/kg IV on Day 8 (with +/- 2 days window), and 15 mg/kg IV on Day 15. The subcutaneous (SC) administration of 600 mg (2 injections of 2 mL CFZ533 at 150 mg/mL) every 2 weeks started on Day 29, in combination with MMF and CS up to EOS.

Group Type EXPERIMENTAL

CFZ533

Intervention Type BIOLOGICAL

Comparison with standard of care immunosuppression

CFZ533 300 mg regimen

Single loading dose of 30 mg/kg IV on Day 8 (with +/- 2 days window). The SC administration of 300 mg (1 injection of 2 mL CFZ533 at 150 mg/mL) every 2 weeks started on Day 29, in combination with MMF and CS up to EOS.

Group Type EXPERIMENTAL

CFZ533

Intervention Type BIOLOGICAL

Comparison with standard of care immunosuppression

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CFZ533

Comparison with standard of care immunosuppression

Intervention Type BIOLOGICAL

Tacrolimus - MMF - corticosteroids

Standard of care immunosuppresive regimen

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Screening period up to liver transplantation:

* Written informed consent obtained before any assessment.
* Male or female patients between 18 to 70 years of age.
* Recipients of a primary liver transplant from a deceased donor.
* Up to date vaccination as per local immunization schedules.
* Recipients tested negative for HIV.
* MELD score ≤ 30.
* Transplantation to occur within defined screening period following informed consent signature.

At randomization (Day 8 +/- 2):

* Recipients with no active HCV and HBV replication.
* Allograft is functioning at an acceptable level by the time of randomization as defined by AST, ALT and Alkaline Phosphatase levels ≤ 5 times ULN and Total Bilirubin ≤ 2 times ULN.
* Renal function (eGFR, MDRD-4 formula) ≥ 30 mL/min/1.73 m2 based on most recent post-transplant value prior to randomization.
* Recipients who have been initiated on an immunosuppressive regimen that contains TAC, mycophenolate mofetil (MMF) and corticosteroids (CS) as per protocol.

Exclusion Criteria

Screening period up to liver transplantation:

* Use of other investigational drugs at screening within 30 days or 5 half-lives of screening.
* Recipients of multiple solid organ or islet cell transplants, or recipients that have previously received a tissue transplant, or a combined liver-kidney transplant.
* Recipients of a liver from a donor after cardiac death (DCD), from a living donor, or of a split liver.
* Recipient who tested negative for Epstein Barr virus (EBV) within 28 days prior to baseline visit.
* Recipients receiving an ABO incompatible allograft.
* History of malignancy of any organ system (except hepatocellular carcinoma (HCC) or localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there was evidence of local recurrence or metastases.
* Hepatocellular carcinoma that did not fulfill Milan criteria (1 nodule ≤ 5 cm, 2-3 nodules all ≤ 3 cm, without evidence of metastatic disease or vascular invasion) at the time of transplantation.
* Recipients transplanted for acute liver failure (does not apply to acute on chronic liver failure).
* Any use of antibody induction therapy, or use of any immunosuppressive medications (or other medications prohibited by the protocol).
* Patients who have received a live vaccine within four weeks prior to transplantation.
* Recipients with HIV positive donor.
* Recipients with donors HBsAg positive.
* Recipients who were HCV antibody-positive without documented sustained viral response (SVR) at 12 weeks after finishing anti HCV treatment (e.g., direct-acting antivirals).
* Recipients with HCV RNA-positive donors.
* Recipients with donors with macrovesicular steatosis \> 30%.
* Pregnant or nursing (lactating) women.

At randomization (Day 8 +/- 2):

* Any post-transplant history of thrombosis, occlusion or stent placement in any hepatic arteries, hepatic veins, portal vein or inferior vena cava at any time during the run-in period prior to randomization. Absence of any graft vascular thrombosis or occlusion (by diagnostic method used at the site to assess vascular patency) must be confirmed by imaging prior to randomization.
* Recipients with platelet count \< 50,000/mm3.
* Recipients with an absolute neutrophil count of \< 1,000/mm³ or white blood cell count of \< 2,000/mm³.
* Recipients with clinically significant systemic infection requiring use of intravenous (IV) antibiotics.
* Evidence of active tuberculosis (TB) infection.
* Recipients who are in a critical care setting at the time of randomization requiring life support measures such as mechanical ventilation, dialysis, requirement of vasopressor agents.
* Recipients who were on renal replacement therapy at randomization.
* Any episode of acute rejection or suspected rejection prior to randomization.
* HCC patients whose explanted liver graft pathology report shows (i) pathologic Tumor-Node-Metastasis (pTNM) stage beyond T2N0M0, (ii) presence of mixed carcinoma, (iii) microvascular invasion despite pTNM stage.
* Patients with body weight \< 30 kg or \> 180 kg.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No